ABSTRACT: Peri-prosthetic joint infection (PJI) is one of the most serious and dreaded complications after total joint replacement (TJR). Due to an aging population and the constant rise in demand for TJR, the incidence of PJI is also increasing. Successful treatment of PJI is challenging and is associated with high failure rates. One of the main causes for treatment failure is bacterial biofilm formation on implant surfaces and the adherence of biofilm bacteria on tissue and bone next to the implant. Biofilms are protective shields to bacterial cells and possess many unique properties that leads to antibiotic resistance. New therapeutic platforms are currently being explored to breakdown biofilm matrix in order to enhance the efficacy of antibiotics. Bacteriophages (phages) is one of these unique therapeutic platforms that can degrade biofilms as well as target the killing of bacterial cells. Preclinical studies of biofilm-mediated infections have demonstrated the ability of phage to eradicate biofilms and clear infections by working synergistically with antibiotics. There is strong preclinical evidence that phage can reduce the concentration of antibiotics required to treat an infection. These findings support a promising role for phages as a future clinical adjunct to antibiotics. In addition, phage therapy can be personalized to target a specific bacterial strain. Clinical studies using phage therapy are limited in Western literature; but phase I studies have established good safety profile with no adverse outcomes reported. In order to translate phage therapy to treat PJI in clinics, further preclinical testing is still required to study optimal delivery methods as well as the interaction between phage and the immune system in vivo. ß
According to an investigation performed by the Agency for Health Research and Quality (AHRQ) it is projected that there are over one million total joint replacements (TJR) performed annually in the United States. 1 With an aging yet still active population, the number of TJR surgeries is expected to grow exponentially over the next few years. Although these procedures are extremely beneficial for patients with disabling joint disease, they are also associated with very high risks. Peri-prosthetic joint infection (PJI) is one of the most serious and dreaded complications after TJR. The average rate of PJI within 2 years after TJR is 1-2.0% for primary replacements, and can be as high as 14% for revision surgeries. 2 The current standard treatment for PJI is the complete removal of an infected implant, followed by a prolonged course of systemic antibiotic therapy in order to eradicate the infection prior to re-implanting a new prosthetic joint. The success rates of eradicating PJI using current standard treatment methods vary between 60% and 80% at 2 years. 3 Treating PJI incurs a substantial burden on patients and the health system. This disease negatively impacts patients' quality of life and, in extreme circumstances, can lead to the loss of their limb and life. PJI also causes significant financial stress on the health system. Based on an economic analysis by Bozic and colleagues, the annual cost of treating PJI to US hospitals has increased from $320 million to $566 million over the span of 8 years. 4 The cost of treating PJI is also projected to exceed $1.62 billion in the United States by 2020. 4 Risk factors for treatment failure of PJI are multifactorial, and are associated with chronic infections, immune compromised patients, and most importantly antibiotic resistance. The National Institute of Health (NIH) has recently highlighted the growing threat of antibiotic resistance. According to a recent report published in 2014 by the NIH, antibiotic resistance has accelerated at an alarming rate over the past decade. 5 There has been a considerable decline in the rate of discovery and development of alternative antibiotics by pharmaceutical companies to overcome resistant bacteria. This gap in therapy has stimulated the exploration of alternative antimicrobial strategies that can outsmart bacterial mechanisms, which induce antibiotic resistance, such as biofilm formation.
Emerging evidence has shown that biofilms play a key role in the pathophysiology of PJI and antibiotic resistance. [6] [7] [8] [9] [10] [11] Biofilms are surface attached communities of bacterial cells that possess defense mechanisms that make them more difficult to detect and eradicate using conventional conventional therapies. Biofilm can be found on implanted hardware and biofilm bacteria can adhere to surrounding tissue and the bone next to the implant. 12, 13 This is problematic as the formation of biofilm can elevate the minimal inhibitory concentration of antibiotics necessary to control the infection up to a 1,000-fold, compared to non-biofilm cells.
14 Therefore, new methods for antimicrobial therapy that focuses on disrupting biofilms are needed to overcome antibiotic resistance and enhance the efficacy of treating PJI. A unique antimicrobial strategy described in the literature is the utilization of lytic bacteriophages (phages). Phages are naturally occurring viruses that can target and kill bacteria, and can destroy biofilm matrix. Preclinical research has demonstrated that phages possess unique capabilities for targeting bacterial infections by breaking down biofilms. 15 Phages can also be genetically modified to enhance their antibacterial effect. Phase I clinical trials utilizing phage conducted in the US and the UK on humans have demonstrated excellent safety profiles. [16] [17] [18] This current review will summarize the most current concepts of biofilm pathophysiology and its mechanism of antibiotic resistance. It will provide a comprehensive summary and discussion of all the preclinical and clinical studies published on bacteriophage therapy against biofilm infections.
Pathogenesis of Biofilm Formation on Implants
Bacterial cells have a high affinity for adhering to foreign materials commonly used in orthopedics, including cobalt-chromium, titanium, polyethylene, and poly (meythyl methacrylate) (PMMA). 19 Once these cells adhere, they start to aggregate in communities and produce a matrix of extra-polysaccharides (EPS), proteins, and extra cellular DNA (eDNA) to encapsulate the aggregation in the form of a biofilm. 20 Staphylococci species, specifically Staphylococcus aureus and Staphylococcus epidermidis are the most common biofilm-forming bacteria in PJI, representing nearly 50-60% of cultured infections. 21 The life cycle of biofilm formation on implant surfaces is comprised of four key stages (see Fig. 1 ): (i) adhesion of free-floating (planktonic cells); (ii) colony formation; (iii) maturation; and (iv) detachment. The initial step of biofilm formation is the attachment of free planktonic bacteria to the implant surface. The materials and surface roughness commonly used in orthopedic implants, such as titanium and chromium, make them highly susceptible for the initial adhesion of bacterial cells. 19 In addition, the local disruption and trauma of tissues caused by surgery triggers the production of host extracellular matrix proteins (ECM), such as fibronectin and collagen around the surfaces of implants. 22 The deposition of these ECM proteins further enhances bacterial colonization, by enabling bacterial surface proteins to bind to the host protein matrix resulting in anchoring more readily on the implant surface. 22 Surgical trauma also induces local immune suppression due to the disruption of local vascular supply to the tissues, which further facilitates colonization by bacterial cells and reduces the concentration required to cause an infection. 23 Only 100 colony-forming units are needed to cause a PJI. 24 Following adhesion on the implant surface, bacteria begin to develop colonies by aggregating and adhering to each other via intercellular adhesion proteins. 25 At this stage, the aggregation of bacteria up-regulate the production of EPS and embed themselves within the EPS matrix. While in this shielded environment, the biofilm starts to mature and thickens as bacterial cells continue to proliferate to form multilayered colonies. 26 In the maturation phase, there is continued proliferation, and bacteria within the biofilm undergo density dependent changes once a critical threshold is met. This process has been described as quorum sensing (QS). 27 QS act as a complex network of internal highways that connects various colonies within the biofilm microenvironment. Bacterial cells use QS to communicate with one another via cell-to-cell signaling, exchange nutrients as well as virulent genes that promote resistance against antimicrobials and evasion from the immune system. 27 The last step in biofilm lifecycle is detachment of bacterial cells via proteases that help release planktonic bacteria from the biofilm to travel and initiate further infections.
Mechanisms Of Antibiotic Resistance Within A Biofilm
The formation of biofilm can elevate the minimal inhibitory concentration of antibiotics necessary to control the infection up to a 1,000-fold compared to their planktonic counterpart. 14 The proposed theories to describe the mechanism of antibiotic resistance within a biofilm are complex and multifactorial. There are three main factors: (i) physical barrier against host defenses and antibiotic penetration; (ii) decrease metabolic activity of bacterial cells; and (iii) QS enhancing exchange of antibiotic resistance genes.
In order for antibiotics to act on the microorganisms within the film, they must be able to penetrate the EPS matrix. Numerous in vitro studies have shown decreased penetrance of antibiotics within biofilms, especially with Pseudomonas aeruginosa, although this can vary with the antibiotic used. 28 A study by Singh et al. looked into the penetration of various antibiotics into S. aureus and S. epidermidis derived biofilms. Their results confirmed previous studies, of vancomycin (an aminoglycoside) penetration being significantly inhibited, as well as the penetrance of cefotaxime (beta lactam) when exposed to the standard staphylococcal biofilms. 29 The physical structure of biofilms results in the creation of an antibiotic gradient, with inner cells receiving less antibiotic and thus greater opportunity to develop resistance. 30 Furthermore, biofilm bacteria mutate more rapidly than their planktonic counterparts, a phenomenon linked to increased oxidative stress in the biofilm environment both endogenously and induced in response to antibiotics. 30 These adaptive stress responses within biofilms are active processes mediated by QS. 31 Depending on the bacterial strain, QS facilitates the expression of genes and signaling molecules that contribute to antibiotic resistance, such as rendering cells into a dormant state, or the production of enzymes and efflux pumps that inactivate antibiotics. 31 Diminished penetrance is not the only factor; even in studies that have shown effective penetrance of biofilms by antibiotics, there has been a lack of efficacy in eradicating the biofilm. Another hypothesis for antibiotic resistance is related to the diminished growth state found within biofilms. Microorganisms found within the nutrient deprived deeper layers of the biofilm have shown lower metabolic activity and slower growth rate. 32 Studies have shown that there is a correlation between slow growing organisms and decreased sensitivity to antibiotics that target growing cells. 32 Antibiotics require actively multiplying cells in order to kill them, as they rely on interfering with cell metabolism to mediate their bactericidal effects. 33 For example, a study by Duguid et al. demonstrated decreased susceptibility of slow growing S. epidermidis biofilms to tobramycin as compared to free planktonic, and faster growing biofilm forms. 34 Compared to planktonic cells, biofilms contain a higher population of unique slow growing cells known as a persister cells. 35 Persister cells are highly antibiotic tolerant, metabolically dormant non-dividing bacteria that acquire this phenotype in the presence of antibiotics; they retrieve their metabolic activity once antibiotics are removed. 33 Persister cells are significant contributors to the challenges in treating biofilms with antibiotics as they are a source of recurrence in chronic infections. 33 Additionally the heterogeneity of the environment within biofilms, such as pH, metabolites, and oxygen levels can alter the efficacy of antibiotics.
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Bacteriophages and Their Therapeutic Potential
The successful eradication of an established biofilm requires the effective disruption of the EPS matrix, as well as the killing of bacteria cells of varying metabolic states 37 ; phages have the capability of achieving both. They are the most ubiquitous and abundant organisms on Earth, with an estimated total number of 1,032 species of phage on the planet. 38 Phages play an important role in maintaining microbial community balance on the planet. 39 The discovery of phages to treat infections dates back to the early 1900's, 40 however, its popularity as a therapeutic has waned after the discovery of antibiotics. The current increasing prevalence of antibiotic resistant infections has revived the idea of phage therapy as a unique and alternative antimicrobial treatment. Phages are naturally occurring viruses that attack bacteria with high specificity through recognition of bacterial surface proteins with their filamentous tail fibers. 41 They adhere to the surface of bacteria, insert their genomic material and take over metabolism of the bacterial host cell. Phages then go onto replicate within the host cell and produce proteins called endolysins. Endolysins lyse the bacterial cell wall, effectively killing the cell and releasing the phage. The released phages are available to attack additional bacteria. Therefore, phages can be viewed as a self-amplifying therapeutic that possess an inherent ability to degrade biofilm PHAGE THERAPY FOR PROSTHETIC JOINT INFECTION proteins, infect, replicate, and selectively kill bacterial cells.
Because of the high density of bacteria within biofilms, the rate of phage multiplication is increased. 38 As discussed previously, the low metabolic states of bacteria found deeper within the nutrient deprived layers biofilms make them less susceptible to antimicrobial therapy. 32 Although the numbers of virions produced during replication can be decreased when phages infect low metabolic state cells, 42 their susceptibility to infection by phages is not compromised by low nutrient states. 42, 43 Phages also have the ability to infect persister cells, and kill them once they become metabolically active again. 44 In addition to their bactericidal properties, phages possess the ability to disrupt the EPS matrix by producing endolysins and EPS depolymerase that can hydrolyze the biofilm matrix. 45 This ability can facilitate better penetration of antibiotics to attack bacteria hiding within the biofilm.
45,46
Pre-Clinical Applications of Phage Therapy in Bone Related Infections Currently there are very limited pre-clinical in vivo studies published on phage therapy in the context of bone related infections. Table 1 summarizes the only three studies published in the field to our knowledge. Two studies explore phage therapy in an osteomyelitis model, and the third was in a PJI model. Similar to PJI, osteomyelitis is very challenging to treat, especially in the chronic setting where biofilms play a role. 50 Yilmaz et al. established a biofilm associated osteomyelitis model in rats using methicillin resistant S. aureus (MRSA) and P. aeruginosa. The efficacy of phages, antibiotics, and combination of both therapies to treat the infection were compared. The study identified a synergism between phage and antibiotics, which led to a significant reduction in the burden of biofilm infection formed by both organisms. 47 Although the display of synergism between phage and antibiotics has been demonstrated in vitro [51] [52] [53] this study is the first to demonstrate such a finding in vivo. This study elucidates that using phages clinically as a single therapeutic agent against PJI may not be as successful as using it as an adjuvant to antibiotic therapy. If used as an adjuvant therapy, the next important question is when to administer phages in relation to antibiotics: Concomitantly, pre, or post. To our knowledge, only one study by Chaudhry et al. has investigated order effects of phage and antibiotics to treat biofilms. They demonstrated in an in vitro model that phage therapy preceding antibiotics (in this case, gentamicin and tobramycin) was the most effective treatment regime in reducing P. aeruginosa biofilms. 54 Another in vitro study by Ryan et al. demonstrated that increasing the dosage of phage from 104 to 107 (PFU/ml) was able to reduce the minimum biofilm eradication concentration (MBEC) of cefotaxime from 256 to 32 mg/ml in Escherichia coli biofilms. 51 This observation further adds to the value of phage therapy as a mean of reducing the dose dependant side effects of the high antibiotic concentrations required to treat PJI.
The study by Kaur et al. 49 is the only study that investigated phage therapy in a PJI in vivo model. This infection model was established using MRSA to inoculate a metal pin implanted in the tibial medullary canal of an immune competent mouse. This study looked at prophylactic treatment as the metal pin was coated with phage, antibiotics or a combination of phage and antibiotics prior to its implantation. The author noted that coating the implant with phage and antibiotics provided the best therapeutic results to protect the implant against infection. This presents another potential therapeutic application for phage therapy.
Although the aforementioned studies shed light on the potential therapeutic benefit of phages, there are limitations in their experimentation that need to be addressed. One of the main limitations is the narrow spectrum of bacterial pathogens tested. All three studies focused on MRSA, while only one study tested P. aeruginosa in a non-PJI model. Although S. aureus infections account for the majority of early onset PJI, coagulase-negative staphylococci (CoNS), especially S. epidermidis, are an equal contributor to PJI when factoring both acute and delayed onset PJI. 21 Yet, none of the preclinical studies examined this organism despite its prevalence in PJI, strong biofilm forming capabilities, as well as emerging resistance to antibiotics. 55 Another limitation in the presented preclinical studies is the lack of a true representative in vivo PJI model that replicates the mechanical stresses and joint microenvironment of a clinical setting. Kaur et al. utilized a PJI model where the implant does not bear weight, nor does it sufficiently separate the marrow from the articular space. This limits the ability to translate the preclinical findings into clinics reliably. A new promising in vivo PJI model has been recently published by Carli et al. that replicates the clinical setting of TJR more accurately. 56 This model should be adopted for future testing of anti-biofilm therapies.
A potential limitation for phage therapy arises from the high specificity of each phage toward a certain bacterial strain. Therefore, the accurate diagnosis of the infecting organisms is required to guide the appropriate selection of the phage. To overcome this limitation, the concept of designing phage cocktails has been explored to broaden the spectrum phage therapy. Kishor et al. 48 established an MRSA osteomyelitis rabbit model and treated it with a custom made cocktail of seven phages that were selected based on their virulence against various clinical MRSA strains. This study used phage cocktail as the only treatment modality for the osteomyelitis. This cocktail of phage therapy alone was sufficient to clear the infection in both an acute and chronic setting, with sterility of 
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wound cultures achieved one week after administration. This study demonstrated the opportunity of tailoring phage therapy based on susceptibility testing to target a variety of bacterial strains isolated from patients. There are also concerns regarding the immunogenicity of phage and diminished therapeutic efficacy. Several in vitro studies and in vivo studies have demonstrated that phage can elicit an immune response from both the innate and adaptive immune system [57] [58] [59] and thus present a source of inactivation. However, it should also be noted that phages have varying degrees antigenicity, and low antigenic phages can be engineered or selected for. 41, 60 In the context of treating PJI, these findings become less clear, as in vivo studies describe systemic administration of phages, or in the case of in vitro studies, direct administration of phages into human or animal serum. The in vivo studies and randomized clinical trials examined in depth in this review employed local administration of phage. We envision that phages would be administered locally, not systemically at the site of infection where biofilm would be present. Biofilms may initially afford protection for phage, as the EPS matrix can inactivate anti-phage antibodies, although it is unclear if this would be the case in vivo. 41, 61 However, it should be noted that there are no studies that compare local versus systemic administration of phages, or any studies that quantify anti-phage antibodies in biofilm infections. An additional concern is that an immune response could have adverse side effects. Phages have an excellent safety profile, and there have been no side effects reported in animal and human studies, 41, 60, 62 even when highly antigenic phages are have been administered to immunocompromised patients. 63 Another limitation is that the optimal timing of administering phage therapy is unknown. Most in vivo studies administer treatment after a biofilm has been established, or shortly after the insertion of a preestablished biofilm. There has been no comparison of the efficacy of phage against excessively chronic biofilm infections, which can appear in a clinical setting. Indeed, one of the important topics for future research is how to optimize the timing and method of delivery to enhance the therapeutic effect of phage therapy.
Clinical Trials of Phage of Therapy to Date
The bulk of experience with human phage therapy has been concentrated in Eastern Europe and the former Soviet Union. Western skepticism of phage therapy is partly owing to the fact that many of the reports describing phage therapy from these countries are not accessible in English, and those that are accessible often do not describe well-controlled studies. 62 In the Western world, increasing interest in phage therapy has led to several safety and efficacy trials in humans. There have been three clinical trials conducted in Western nations using phage therapy (Table 2): Two Phase I trials conducted in Belgium and the USA, while a Phase II trial was conducted in the UK. A formal safety study conducted in Switzerland demonstrated no safety concerns when bacteriophages targeting E. coli were orally administered to human volunteers. 64 Similarly, an FDA-approved Phase I physician-led trial was completed at a wound care centre in Lubbock, Texas using a mixture of phages targeting P. aeruginosa, S. aureus, and E. coli. 17 This study also revealed no increase in adverse reactions associated with application of phage cocktails.
These phase I studies paved the way for the first fully regulated, placebo-controlled, double-blinded, randomized Phase II clinical trial for phage therapy in the Western world. The investigation was conducted in the UK in 2009 was a randomized double-blinded study which demonstrated efficacy and safety of phages. This study looked at outcomes in treating antibiotic resistant chronic otitis media infections, with a cocktail of six phages targeting P. aeruginosa. Measurable therapeutic effects were achieved with minimal dosing and the phage demonstrated good replication. Only a single topical application at a dose that translates to nano grams of phage was used 18 and the average phage count over 42 days was 200 times the initial input dose. 18 Although larger studies will be required to validate the efficacy of phages, these initial clinical trials suggest a promising role for phage therapy in treating PJI.
CONCLUSION
Patients undergoing TJR are vulnerable to developing PJI. The morbidity and cost associated with PJI treatment poses a growing burden on our patients and the health care system. Failure rates of treating PJI can be as high as 40%. One of the main contributors to treatment failures is antibiotic resistance caused by biofilm-based infections. Treatment failure of PJI due to antibiotic resistance isn't limited to the field of orthopedics, but extends to other surgical specialities that rely on prosthetic implants to manage patients. The current treatment protocol to eradicate PJI uses a shot-gun approach by administering long-term systemic antibiotics, however, they are frequently unable to reach minimum inhibitory concentrations at sites of function due to the presence of biofilms. This growing problem of antibiotic resistance has led to resurgence in exploring alternative strategies that possess unique and versatile antimicrobial properties. One of these strategies is the use of phages to eradicate the bacteria residing in biofilms.
Phage therapy represents a unique therapeutic platform for treating the growing concern of PJI. Preclinical and clinical studies using phage therapy have demonstrated very good safety profile as well as promising therapeutic effect, especially when combined with antibiotics, as both agents can work synergistically against biofilms. Phages can be genetically modified to improve its antibacterial activity. Phages can also target specific pathogens at localized sites of infection, breakdown biofilm formation and self-amplify their local concentration to achieve a powerful therapeutic effect. This targeting therapeutic feature of phages can open the door for implementing personalized antibacterial therapy by which the most effective phage or combination of phages can be selected to kill specific strains of antibiotic resistance bacteria isolated from PJI patients. This tailored therapy can be achieved by developing a phage library from which a high throughput screening technology can select the most effective combination therapies of phages to kill resistant bacterial strains. Figure 2 represents a depiction of this tailored therapeutic model.
Despite these promising preclinical and clinical results, further research is necessary to investigate important questions. There have been no studies to assess the most effective methods or routes for delivery. Another area to investigate is the optimal number of treatment dosages required for the phage to have maximum efficacy. Further research is also needed to investigate how the host immune system responds to multiple phage treatments and whether antibodies can neutralize phage. To improve on the translatability of preclinical results, we recommend using more representative in vivo PJI models that better replicate the peri-prosthetic environment joint environment.
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